Literature DB >> 7654787

Methadone maintenance treatment: an update.

G Bertschy1.   

Abstract

Available data (this review includes old major articles and recent articles) show that, although results are heterogeneous, methadone maintenance treatments (MMTs) have a real efficiency not only to reduce illicit opiate abuse (50-80% of patients under MMT did not use heroin in the preceding month) but also to reduce criminality, HIV risks and mortality, and to improve social rehabilitation, without inducing other alternative substance abuse. A minority of patients (perhaps 5-20%) stay on MMT on a very long-term basis (more than 10 years). Efficiency of MMTs are rather poorly related to patients' variables, with the exception of a moderately deleterious effect of a low age at onset of opiate dependence, a precocious or high involvement in criminality and an abuse of non-opiate drugs. On the other hand, variables related to treatment play a more important role in explaining heterogeneity of results. Optimal daily dose, high quality of medical and psycho-social services, clear orientation towards social rehabilitation and treatment retention (to allow a sufficient duration of treatment) and slow detoxification regimen of well-stabilized patients are all factors contributing to better results.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7654787     DOI: 10.1007/bf02190738

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  95 in total

1.  The use of plasma levels to optimize methadone maintenance treatment.

Authors:  N Loimer; R Schmid
Journal:  Drug Alcohol Depend       Date:  1992-08       Impact factor: 4.492

2.  Serum levels of methadone in maintenance clients who persist in illicit drug use.

Authors:  J Bell; P Bowron; J Lewis; R Batey
Journal:  Br J Addict       Date:  1990-12

3.  Cocaine abuse among methadone-maintained patients.

Authors:  A Oliveto; T Kosten; R Schottenfeld; D Ziedonis
Journal:  Am J Psychiatry       Date:  1993-11       Impact factor: 18.112

4.  Descriptive analysis of cocaine use of methadone patients.

Authors:  M Kidorf; M L Stitzer
Journal:  Drug Alcohol Depend       Date:  1993-05       Impact factor: 4.492

5.  Detected heroin use in an Australian methadone maintenance program.

Authors:  J R Caplehorn; D K Reilly; A Wodak
Journal:  J Subst Abuse Treat       Date:  1993 Nov-Dec

6.  A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE.

Authors:  V P DOLE; M NYSWANDER
Journal:  JAMA       Date:  1965-08-23       Impact factor: 56.272

7.  Outcome of contingency contracting for illicit drug use in a methadone maintenance program.

Authors:  A J Saxon; D A Calsyn; D R Kivlahan; D K Roszell
Journal:  Drug Alcohol Depend       Date:  1993-02       Impact factor: 4.492

8.  Withdrawal from methadone maintenance. Rate of withdrawal and expectation.

Authors:  E C Senay; W Dorus; F Goldberg; W Thornton
Journal:  Arch Gen Psychiatry       Date:  1977-03

9.  Methadone concentrations in plasma and their relationship to drug dosage.

Authors:  K Wolff; M Sanderson; A W Hay; D Raistrick
Journal:  Clin Chem       Date:  1991-02       Impact factor: 8.327

View more
  18 in total

1.  Injection drug use and preventive measures: a comparison of Canadian and western European jurisdictions over time.

Authors:  B Fischer; J Rehm; T Blitz-Miller
Journal:  CMAJ       Date:  2000-06-13       Impact factor: 8.262

2.  Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study).

Authors:  Benedikt Fischer; Jürgen Rehm; Suzanne Brissette; Serge Brochu; Julie Bruneau; Nady El-Guebaly; Lina Noël; Mark Tyndall; Cameron Wild; Phil Mun; Dolly Baliunas
Journal:  J Urban Health       Date:  2005-05-04       Impact factor: 3.671

3.  Methadone treatment for opiate addicts.

Authors:  J L Sorensen
Journal:  BMJ       Date:  1996-08-03

Review 4.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Methadone maintenance treatment can be provided in a primary care setting without increasing methadone-related mortality: the Sheffield experience 1997-2000.

Authors:  Jenny Keen; Phillip Oliver; Nigel Mathers
Journal:  Br J Gen Pract       Date:  2002-05       Impact factor: 5.386

6.  Does methadone maintenance treatment based on the new national guidelines work in a primary care setting?

Authors:  Jenny Keen; Phillip Oliver; Georgina Rowse; Nigel Mathers
Journal:  Br J Gen Pract       Date:  2003-06       Impact factor: 5.386

Review 7.  Interindividual variability of methadone response: impact of genetic polymorphism.

Authors:  Yongfang Li; Jean-Pierre Kantelip; Pauline Gerritsen-van Schieveen; Siamak Davani
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 8.  Exercise as an adjunct treatment for opiate agonist treatment: review of the current research and implementation strategies.

Authors:  Jeremiah Weinstock; Heather K Wadeson; Jaci L VanHeest
Journal:  Subst Abus       Date:  2012       Impact factor: 3.716

9.  Fatal methadone toxicity: potential role of CYP3A4 genetic polymorphism.

Authors:  Lauren L Richards-Waugh; Donald A Primerano; Yulia Dementieva; James C Kraner; Gary O Rankin
Journal:  J Anal Toxicol       Date:  2014-10       Impact factor: 3.367

10.  Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.

Authors:  Matisyahu Shulman; Tse-Hwei Choo; Jennifer Scodes; Martina Pavlicova; Jonathan Wai; Patrick Haenlein; Babak Tofighi; Aimee N C Campbell; Joshua D Lee; John Rotrosen; Edward V Nunes
Journal:  J Subst Abuse Treat       Date:  2021-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.